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ISSObjective: To develop a novel and potent fusion inhibitor of HIV infection based on a
rational strategy for synthetic antibody library construction.
Design: The reduced molecular weight of single-domain antibodies (sdAbs) allows
targeting of cryptic epitopes, the most conserved and critical ones in the context of HIV
entry. Heavy-chain sdAbs from camelids are particularly suited for this type of epitope
recognition because of the presence of long and flexible antigen-binding regions
[complementary-determining regions (CDRs)].
Methods: We translated camelid CDR features to a rabbit light-chain variable domain
(VL) and constructed a library of minimal antibody fragments with elongated CDRs.
Additionally to elongation, CDRs’ variability was restricted to binding favorable
amino acids to potentiate the selection of high-affinity sdAbs. The synthetic library
was screened against a conserved, hidden, and crucial-to-fusion sequence on the
heptad-repeat 1 (HR1) region of the HIV-1 envelope glycoprotein.
Results: Two anti-HR1 VLs, named F63 and D104, strongly inhibited laboratory-
adapted HIV-1 infectivity. F63 also inhibited infectivity of HIV-1 and HIV-2 primary
isolates similarly to the Food and Drug Administration-approved fusion inhibitor T-20
and HIV-1 strains resistant to T-20. Moreover, epitope mapping of F63 revealed a novel
target sequence within the highly conserved hydrophobic pocket of HR1. F63 was also
capable of interacting with viral and cell lipid membrane models, a property previously
associated with T-20’s inhibitory mechanism.
Conclusion: In summary, to our best knowledge, we developed the first potent and
broad VL sdAb fusion inhibitor of HIV infection. Our study also gives insights into
engineering strategies that could be explored to enhance the development of antiviral
drugs. Copyright  2016 Wolters Kluwer Health, Inc. All rights reserved.AIDS 2016, 30:000–000Keywords: HIV fusion inhibitor, HR1, single-domain antibody, synthetic library,
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2 AIDS 2016, Vol 00 No 00IntroductionSignificant advances in antiretroviral therapy have
occurred as the approval of the first fusion inhibitor,
T-20 [1]. T-20 peptide derives from the C-terminal region
(HR2) of gp41 fusion protein from HIV643–678(LAI) [2,3].
By competitively binding the N-terminal region (HR1),
T-20 impairsHR1–HR2 interaction [2] and consequently
the formation of the six-helix bundle (6HB) structure,
responsible for HIV fusion (reviewed in Wilen et al. [4]).
Despite the well characterized antiviral potency of T-20,
clinical resistance has been reported in HIV-1-infected
patients [5]. Additionally, T-20 is described as antigenic [6],
highly expensive, protease-susceptible (no oral adminis-
tration), and ‘pharmacokinetically limited’, among other
limitations [7]. Overall, development of novel HIV fusion
inhibitorswith improved biophysical and pharmacokinetic
properties is required.
Antibody fragments emerged to overcome issues
associated with high-molecular weight of native antibody
structure (IgG), mainly the targeting of cryptic epitopes
and the penetration into densely packed tissues. Single-
domain antibody (sdAb) is currently the smallest functional
antibody fragment, only constituted by the antibody
heavy-chain or light-chain variable domains (VH or VL)
[8]. Additionally to the reduced size, complementary-
determining regions (CDRs; antigen-binding regions) of
dAbs can be easily engineered to develop specific and high-
affinity binders. sdAbs also present excellent biophysical
properties, such as high stability, solubility, and low toxicity
[9]. Despite these beneficial features, only the therapeutic
potential of VH domains have been intensively explored
[10]. Nevertheless, several reports have demonstrated that
VL domains present excellent biophysical properties,
such as high expression yield, resistance to aggregation and
proteases, stability, and high reversibility of thermal
unfolding, in some cases better than VHs [11–14].
Moreover, the stability of VL domains was further
evidenced by the proved functionality of these dAbs in
the absence of disulfide bonds [15,16] or in the reducing
cellular environment [17,18].
Here, we engineered a VL sdAb with elongated CDRs
that broadly and potently inhibits HIV-1 infection by
targeting a well conserved and crucial-to-fusion sequence
on HR1. Despite the clinical resistance to HR1-targeting
T-20, this region contains highly conserved residues
among HIV-1 subtypes and isolates [19], representing
a major target to HIV infection impairment. Anti-HR1
VLs were selected by phage display technology from a
restricted combinatorial library. Epitope mapping of the
twomost potent antiviral VLs – selected against an HIV-1
laboratory-adapted strain – showed that these inhibitors
target a highly conserved and critic region within HR1.
One VL (F63) showed high potency to inhibit HIV-1 and
HIV-2 primary isolates with comparable T-20 activity.
For last, we demonstrated that F63 also interacts with lipidmembranes, a key ability of potent HIV entry inhibitors
[20,21] that correlates with their mechanism of action.Methods
Inhibition assays
HIV-1 laboratory-adapted strain NL4-3 (HIV-1NL4-3)
productionwas performed as described [22] and 50% tissue
culture infectious dose determined as Borrego et al. [6].
HIV-2 and HIV-1 primary isolates from subtypes J and H
were obtained fromBorrego et al. [6]. HIV-1 variantNL4-
3 D36G (parental) and HIV-1 variants resistant to T-20
NL4-3 (D36G) V38A/N42D and V38A/N42T (NIH
AIDS Reagent Program) were propagated accordingly to
Borrego et al. [6]. HIV-1 primary isolates from subtypes B
and C were obtained from Calado et al. [23].
For all the inhibition assays, viruses or HeLa243env/
HeLa273Denv cells were incubated with titrated amounts
of the inhibitors during 1 h at 378C prior to infection and
HIV infectivity was measured 48 h postinfection. In
Jurkat E6-1 (NIH AIDS Reagent Program) inhibition
assay, HIV p24CA concentrations were measured by
ELISA (NCI, Frederick, Maryland, USA) according to
manufacturer’s instructions. In inhibition assays with
TZM-bl cells (NIH AIDS Reagent Program) [6],
luciferase or ‘b-galactosidase’ expression was quantified
with the One-Glow luciferase assay substrate reagent
(Promega, USA) according to manufacturer’s instructions
or as described in Da Silva et al. [24], respectively.
Cell–cell fusion assay was adapted from Schwartz et al.
[25]. HeLa243env or HeLa273Denv cells [25] were
cocultured at a 1 : 1 ration with multinuclear activation
of a galactosidase indicator (MAGI) cells (NIH AIDS
Reagent Program) in the presence of inhibitors. After
48 h, ‘b-galactosidase’ expression was quantified as
described [24].
Peripheral blood mononuclear cells’ isolation, mainten-
ance, and inhibition assays were performed as previously
described [23] with the following exception: at 7 days
postinfection, HIV p24CA concentrations were measured
by ELISA. The 50% inhibitory concentration (IC50)
estimation and statistical analysis were performed as
described [6,26].
The remaining experimental procedures are provided in
the Supplementary Methods (http://links.lww.com/
QAD/A912).
Results
Selection of anti-HIV VLs with elongated
complementary-determining region 1 and
complementary-determining region 3
In contrast to regular binding regions, long and flexible
CDR3 of camelid heavy-chain antibodies [27] can
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evasion) epitopes [9,28]. We proposed to translate these
CDR features to a noncamelid scaffold – a rabbit k VL
domain [29] derived from a previously selected single-
chain variable fragment [30]. In addition to the stability
already attributed to VL sdAbs [11–14], their solubility
seems less affected by sequence variation in CDRs than
VH domains [14]. We chose a nonhuman domain
because of the extensive CDR3 length heterogeneity
naturally present in the k light chains of rabbit antibodies,
in contrast with human ones [31,32]. Furthermore, this
particular VL domain was shown to be highly stable and
soluble in the absence of its counterpart VH domain [29].
The naturally longer and most exposed CDR of parental
VL (CDR3; Fig. S1A, http://links.lww.com/QAD/
A912), hereafter named VLparental, was grafted with a
series of long CDRs containing a well characterized
paratope for hen egg-white lysozyme [33] flanked by
sequences of serines/glycines. These small amino acids –
major contributors to conformational flexibility of
antibody CDRs [34,35] – were added to elongate the
original CDR3 of 11 amino acids to 22, 26, or 30 amino
acids (Fig. S1B, http://links.lww.com/QAD/A912).
Evaluation of VLparental functionality in the presence of
an elongated CDR3 is presented in Supplementary
Information.
After validation of VLparental functionality in the presence
of an elongated CDR3, we used it as a scaffold for
synthetic library construction. This library was designed
to select anti-HIV minimal antibody fragments with
high-affinity toward a cryptic HR1 region. We chose to
elongate both CDR1 and CDR3 to increase theoretically
the affinity of the selected dAbs and at the same time
avoid unspecific binding from the original CDR1. For
the CDRs library construction, we used the previously
validated strategy for hen egg-white lysozyme paratope
grafting (Fig. 1a), restricted randomization of the central
12 amino acids with a degenerate codon (DVN) that only
encodes for 12 of the canonical 20 amino acids. As most
encoded amino acids by DVN codon were described as
abundant in natural CDRs and antigenic contacts [36],
we expected to improve the selection of high-affinity
sdAbs. Moreover, these amino acids seem to be sufficient
to generate high-affinity and specific minimalist synthetic
binders [35,36]. A library of 8.0 109 clones was
generated, cloned, and selected by phage display against a
crucial-to-fusion, difficult-to-access, and well conserved
sequence on HR1 (HR1546–581(HXB2)), named N36 [19]
(Fig. S2, http://links.lww.com/QAD/A912). Apart from
the cryptic nature of the entire HR1 region, N36
comprises residues of a particularly deep cavity, named
hydrophobic pocket, described as highly conserved and a
hot spot for neutralization of HIV-1 infection [19,37].
Despite the therapeutic interest, this pocket is particularly
difficult to target in an infection context because of its
extreme concave conformation. As shown in Fig. 1b, we
isolated five VLs with strong binding to HR1 from the329 clones screened by ELISA. A further characterization
of HR1 binding showed a dose-dependent binding
for all five selected VLs (Fig. 1c and Table S2, http://
links.lww.com/QAD/A912). A competitive ELISA
demonstrated that the five VLs showed a decreased
binding to immobilized HR1 as the soluble HR1 amount
increased, confirming VLs specificity of recognition
(Fig. 1c).
To assess the antiviral activity of selected VLs, we
performed a second screening (‘functional screening’)
against HIV-1NL4–3 – encoding the G547D mutation
responsible for less susceptibility to T-20 fusion inhibitor
[38]. From the five anti-HR1 VLs, F63 and D104
inhibited HIV-1NL4–3 infectivity by 90% (Fig. 1d) and
were selected for further characterization of antiviral
activity. Except for CDR1 of VL D103 that was not
randomized, DNA sequencing analysis confirmed that all
CDR1 and CDR3 sequences of the five anti-HR1 VLs
were unique (Fig. 1e). F63 and D104 VLs were expressed
and purified in high yield and used for further functional
characterization (Fig. S3, http://links.lww.com/QAD/
A912).
Epitope mapping of antiviral VLs
Epitopes of F63 and D104 were mapped by ELISA, using
a set of 10 overlapping synthetic peptides covering the
template HR1 (Fig. 2a), and compared with the T-20
binding region. Both VLs exhibited similar target
sequences within the central region of N36 with short
overlap at the C-terminus of T-20 binding region (Fig. 2b
and c). F63 showed the strongest binding to peptide
5 (NH2-EAQQHMLQLTVWGIK-COOH), suggesting
that it might contain its epitope (Fig. 2b). D104 showed
similar binding to peptides 5 and 6 (Fig. 2b), indicating
that its epitope is located within the overlapping sequence
of 11 amino acids NH2-HMLQLTVWGIK-COOH
(Fig. 2a).
Antiviral activity of VLs
The antiviral activity of VLs was first compared with
T-20peptide against theHIV-1NL4–3.T-20 alsobindsHR1
impairing the virus–cell fusion driven by HR1–HR2
interaction, an inhibition mechanism we reasoned to be
similar to selected anti-HIVVLs. As shown in Fig. 3a, both
F63 and D104 strongly inhibited HIV-1NL4–3 infection in
TZM-bl cells (IC50 was 0.5 0.2 nmol/l for F63 and
9.7 5.4 nmol/l for D104). Remarkably, F63 was more
active against HIV-1NL4–3 than D104 and T-20 (IC50 was
0.5 0.2 nmol/l for F63 vs. 9.7 5.4 nmol/l forD104 and
3.1 1.9 nmol/l for T-20). As expected, the VLparental did
not inhibit HIV-1NL4–3. F63 and D104 also strongly
inhibited HIV-1 infection similarly to T-20 in Jurkat cells
(IC50 was 0.1 0.01 nmol/l for F63, 0.6 0.1 nmol/l for
D104, and 0.1 0.01 nmol/l for T-20; Fig. 3b). No
cytotoxicity was observed when either TZM-bl or Jurkat
cells were incubated with the highest concentration
of the VLs (Fig. S4, http://links.lww.com/QAD/A912).
CE: Tripti; AIDS-D-15-01276; Total nos of Pages: 11;
AIDS-D-15-01276
4 AIDS 2016, Vol 00 No 00
Ab
s 4
05
 n
m
Ab
s 4
05
 n
m
0.5
0.4
0.3
0.2
0.1
0.0
C62 D103 F63 D104 G54 No VL
Anti-HR1 VLs
100
80
60
40
20
0
C62 D103 F63 D104 G54 No VLVL
Anti-HR1 VLsCompetitor HR1 (pmol)[Anti-HR1-VL] (nmol/l)
Framework 1
C62
D103
F63
D104
G54
VL
C62
22 aa
12 aa (synthetic paratope) 12 aa (synthetic paratope)
22 aa
Framework(a)
(c) (d)
(d)
(b)
CDR1 CDR2 CDR3 His6 HA
D103
F63
D104
G54
VL
C62
D103
F63
D104
G54
Framework 2CDR1 CDR2
Framework 3 Framework 4CDR3
%
 In
hi
bi
tio
n 
of
 in
fe
ct
io
n
1001.8
1.6
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0
101 102 103 104
80
60
40
20
0
0 10 20 30 40 50%
 Im
m
ob
iliz
e
d-
HR
1 
bi
nd
in
g
Fig. 1. Selection of anti-HIV VLs from the constructed synthetic library. (a) Schematic representation of VLs synthetic library. CDR1
and CDR3 were randomized in the central 12 amino acids represented by the X letter in grey. Serines/glycines sequence was added
to the flanks to provide flexibility. The hexahistidine tail (His6) was used for further purification of the VLs and hemagglutinin peptide
sequence tag for detection. (b) Anti-HR1VLs selection. The anti-HR1VLswere expressed in bacteria and cell extracts incubatedwith
N36 region of HR1 or BSA in ELISA plates. No VL represents no VL expression. The five phage-selected VLs out of 329 that presented
highest binding values to HR1 are represented. Data are displayed as Abs measurement at 405nm. To facilitate data representation,
HR1 binding was calculated according to the following formula: AbsHR1-coated well AbsBSA-coated well. (c) HR1-binding analysis.
Increasing concentrations of the purified five selected VLs and control VLparental (VL) were incubated with HR1 or BSA-coated wells
(left). Data are displayed as Absmeasurement at 405nm. To facilitate data representation, HR1 binding was calculated according to
the following formula: AbsHR1-coated well AbsBSA-coated well. Error bars correspond to SD (n¼ 3). Competitive ELISA (right). The five
selected VLs and VLparental (VL) were preincubated with increasing quantities of soluble N36 region of HR1 at 378C. After 1 h, this
mixture was incubated with N36-coated wells (immobilized-HR1). Data are displayed as percentage of immobilized-HR1 binding
(no competitor/immobilized-HR1¼100%) according to formula: [(Abscompetitor/immobilized-HR1Abscompetitor/immobilized BSA)/
(Absnocompetitor/immobilized-HR1Absnocompetitor/immobilized BSA)]100. Error bars correspond to SD (n¼3). (d) Selection of antiviral
VLs. TZM-bl cells were infected with HIV-1NL4–3 laboratory-adapted strain in the anti-HR1 VLs presence (C62, D103, F63, D104,
and G54). TZM-bl cell line expresses ‘b-galactosidase’ gene under control of HIV-1 promoter (long terminal repeat) – activated in
the presence of HIV transactivator of transcription (Tat) protein (infection). VLparental (VL) represents the negative control. No VL
represents no VL expression. Data are displayed as percentage of infectivity inhibition (virus/no inhibitors¼0% inhibition; no virus/
no inhibitors¼background) according to the formula: [(Absvirus/inhibitorsAbsbackground)/(Absvirus/noinhibitorsAbsbackground)]100.
Error bars correspond to SD (n¼2). (e) Amino acid sequences of the five anti-HR1 VLs: C62, D103, F63, D104, G54, and control
VLparental (VL). CDR1 is highlighted in red, CDR2 in yellow, and CDR3 in blue. VLs backbone composed of four frameworks is
represented in grey. CDR, complementary-determining region; SD, standard deviation.
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Fig. 2. Epitope mapping of antiviral VLs. (a) Amino acid sequences of the 10 peptides (15-mer) representing the HR1 template
(N36 in blue) used as antigens tomap the F63 andD104 epitopes. Each peptide comprises 15 residues, 11 amino acids overlapping
the subsequent peptide, and an overhang of four amino acids at N-terminal region. (b) Epitopemapping of F63 andD104 by ELISA,
using 10 overlapping peptides of HR1 region and BSA as antigens and VLparental (VL) as negative control. Data are displayed as Abs
measurement at 405nm. To facilitate data representation, HR1 binding was calculated according to the following formula:
AbsHR1-coated well AbsBSA-coated well. Error bars correspond to SD (n¼3). (c) Location of predicted F63 and D104 epitopes in HR1
region. Amino acid residues in red constitute the T-20 origin and sequence. Amino acid residues highlighted in blue represent the
N36 region. Dash lines represent HR1–HR2 interactions. SD, standard deviation.We also assessed F63 antiviral activity as a dimer.
Surprisingly, F63 dimer did not inhibit HIV-1NL4–3
infection (data not shown), which is probably related to
steric restrictions in F63 epitope access.
We then asked whether F63 and D104 could inhibit
cell–cell fusion between Env-positive cells (HeLa243env)
and adjacent CD4-expressing cells (MAGI) [25]. Similar
to T-20 and in contrast to VLparental, F63 and D104
impaired HeLa cell–cell fusion in a concentration-
dependent manner (Fig. 3c). Fusion between control
HeLa273Denv – without Env expression – and MAGI
cells did not occur (data not shown). These results
emphasize HIV-1 fusion as the target of F63 and D104.
To test the hypothesis that F63 and D104 were as active as
T-20 toward clinically relevant HIV isolates, the IC50 of
VLs was evaluated against two HIV-1 and HIV-2 primary
isolates in TZM-bl cells. HIV-1 primary isolates belong to
distinct subtypes of the major HIV-1 group M, clade
J (93AOHDC250) [26] and clade H (93AOCA251) [26].
HIV-2 primary isolates 03PTHCC12 and 10PTHSMNC
[26] belong to the most prevalent HIV-2 group [39]
(group A,90% worldwide). Despite the divergent HR1
sequences of the HIV-1 primary isolates (Fig. S2, http://
links.lww.com/QAD/A912), F63 neutralized both
viruses (IC50 was 402 46 nmol/l for 93AOHDC250
isolate and 469 41 nmol/l for 93AOCA251 isolate;
Fig. 4a). Although F63 did not inhibit these HIV-1
primary isolates as potently as T-20, IC50 values are in the
nanomolar range for both HIV-1 subtypes (IC50 was402 46 nmol/l for F63 vs. 1.3 0.4 nmol/l for T-20 for
93AOHDC250 isolate; 469 41 nmol/l for F63 vs.
0.4 0.1 nmol/l for T-20 for 93AOCA251 isolate;
Fig. 4a and c). This fact still supports F63 as a potent
inhibitor of these two HIV-1 primary isolates. In contrast
to T-20, F63 also inhibited the two HIV-2 primary
isolates in the nanomolar range (IC50 was 460 19 nmol/
l for F63 vs. 2855 483 nmol/l for T-20 for
03PTHCC12 isolate; IC50 was 433 38 nmol/l for
F63 vs. 266 25 nmol/l for T-20 for 10PTHSMNC
isolate; Fig. 4b and d). In contrast to F63, D104 did not
inhibit either HIV-1 or HIV-2 primary isolates (data not
shown). These results suggest that in addition to
inhibition of HIV-1 non-B subtypes, F63 can be a
potent inhibitor of HIV-2 isolates. We also tested the
antiviral potency of F63 in peripheral blood mononuclear
cells against a panel of HIV-1 primary isolates from the
most prevalent subtypes B (developed countries) and C
(developing countries). As shown in Table S3, http://
links.lww.com/QAD/A912, the IC50 values obtained for
F63 were similar to T-20 in the nano–picomolar range.
These results indicate that F63 also potently inhibits
isolates from the most prevalent HIV-1 subtypes in
primary lymphocytes, with comparable activity to T-20.
Overall, F63 was as active as T-20 as judged by the IC50
against all tested HIV isolates (no significant P value;
Fig. 4e). Moreover, F63 was not significantly less active
than T-20 either for HIV-1 or HIV-2 primary isolates (no
significant P value; data not shown). These results indicate
that F63 presents an antiviral activity similar to T-20.
CE: Tripti; AIDS-D-15-01276; Total nos of Pages: 11;
AIDS-D-15-01276
6 AIDS 2016, Vol 00 No 00
%
 In
hi
bi
to
n 
of
 in
fe
ct
io
n
[Inhibitor] (nmol/l)
120
(a)
(b)
(c)
F63
Inhibitor IC50 (nmol/l)
D104
T-20
VL
0.5 ±0.2
9.7 ±5.4
3.1 ±1.9
n.a.
100
80
60
40
20
0
10-4 10-2 100 102 104
%
 In
hi
bi
to
n 
of
 in
fe
ct
io
n
[Inhibitor] (nmol/l)
120
F63
Inhibitor IC50 (nmol/l)
D104
T-20
VL
0.1 ±0.01
0.6 ±0.1
0.1 ±0.01
n.a.
100
80
60
40
20
0
10-4 10-3 10-2 10-1 100 101
%
 In
hi
bi
tio
n 
of
 fu
sio
n
[Inhibitor] (nmol/l)
100
80
60
40
20
0
0.01 1 100 1,500
F63
D104
T-20
VL
Fig. 3. Antiviral activity of VLs. Percentage of viral infection
inhibition was assessed against the laboratory-adapted strain
HIV-1NL4–3 in TZM-bl (a) and Jurkat cells (b). HIV infectivity
was evaluated by b-galactosidase activity measurement
(TZM-bl) or p24CA quantification (Jurkat). Data are displayed
as percentage of infectivity inhibition (virus/noTo test F63 neutralizing activity against HIV-1 strains
resistant to T-20, we evaluated the susceptibility of two
HIV-1 variants displaying well definedmutations for T-20
resistance [38,40]. HIV-1 variants resistant to T-20
derived from HIV-1 NL4-3 D36G (parental) susceptible
to T-20 [38,40]. F63 presented no fold increase of IC50 for
all tested HIV-1 variants resistant to T-20 relative to
parental HIV-1 (IC50 fold increase was 0.66 for NL4-3
(D36G) V38A/N42D; no significant P value and 0.70 for
NL4-3 (D36G) V38A/N42T; no significant P value; Fig.
S5, http://links.lww.com/QAD/A912). In contrast,
T-20 IC50 was reported to present a fold increase of
approximately 3.94 103 and 1.61 104 for HIV-1
variants NL4-3 (D36G) V38A/N42D and V38A/N42T,
respectively, comparing with the parental HIV-1 [6].
These data suggest that F63 could constitute an alternative
in the treatment of patients infected with HIV-1 strains
resistant to T-20.
F63 interaction with lipid membranes
As T-20 antiviral mechanism is associated with membrane
interaction, we also evaluated the lipid-binding capacity
of F63 against membrane model systems mimicking the
major lipids of cellular membrane and cholesterol-rich
viral envelope [41]. In the presence of lipid membranes,
variations in the fluorescent residue emission are typically
associated with protein–membrane interactions [42].
Taking advantage of the tryptophan residue (Trp; position
46 in F63 and 37 in VLparental Fig. 1e), we performed
partition experiments based on the VL quantum yield
variations. Fluorescence emission from F63 Trp decreased
with increasing lipid concentrations of the both
membrane models tested (Fig. 5a and b). The Kp values
retrieved from data fitting with the partition formalism
were in the same order of magnitude for viral envelope
and cell membrane models (Table S4, http://links.lww.
com/QAD/A912). The Kp correlates with the extent
of protein interaction with the lipid membrane models –
ratio between the concentration of a given molecule in
two separate and immiscible phases. In contrast, we did
not observe variations in the fluorescence emission of
VLparental Trp (Fig. 5a and b). These results suggest thatinhibitors¼0% inhibition; no virus/no inhibitors¼back-
background) according to the formula: [1 (Absvirus/inhibitors
Absbackground)/(Absvirus/noinhibitorsAbsbackground)]100.
Error bars correspond to SD (n¼ 3). (c) Cell–cell fusion assay.
HeLa cells presenting functional gp120/gp41 complexes at
cell surface and expression of HIV-1 transactivator of tran-
scription (Tat) protein (HeLa243env) were cocultured with
CD4-expressing HeLa cells (MAGI) in the inhibitors presence.
Fusion inhibition was assessed by b-galactosidase activity
measurement. Data are displayed as percentage of fusion
inhibition (HeLa243env cells/no inhibitors¼0%; no
HeLa243env cells/no inhibitors¼background) according to
the formula: [1 (AbsHeLa243env/inhibitorsAbsbackground)/
(AbsHeLa243env/noinhibitorsAbsbackground)]100. Error bars
correspond to SD (n¼3). SD, standard deviation.
CE: Tripti; AIDS-D-15-01276; Total nos of Pages: 11;
AIDS-D-15-01276
Synthetic light-chain antibodies Cunha-Santos et al. 7
120
(a) (b)
(c) (d)
(e)
100
80
60
HIV−1 isolate
93AOHDC250 402 ±46
469 ±4193AOHDC251
IC50 (nmol/l) HIV−2 isolate
03PTHCC12 460 ±19
433 ±3810PTHSMNC
IC50 (nmol/l)
40
20
0
−20
−20
[F63] (nmol/l)
%
 In
hi
bi
tio
n 
of
 in
fe
ct
io
n
120
100
80
60
40
20
3000
n.s.
1000
10
8
6
4
2
0
F63 T-20
Inhibitor
2000
0
−20
%
 In
hi
bi
tio
n 
of
 in
fe
ct
io
n
101 102 103 104
120
100
80
60
HIV−1 isolate
93AOHDC250 1.3  ±0.4
0.4 ±0.193AOHDC251
IC50 (nmol/l) HIV−2 isolate
03PTHCC12 2,855  ±483
266 ±2510PTHSMNC
IC50 (nmol/l)
40
20
0
−20
120
100
80
60
40
20
0
10−4 10−2 100 102 104
[T-20] (nmol/l)
10−1 101 103 105
[T-20] (nmol/l)
%
 In
hi
bi
tio
n 
of
 in
fe
ct
io
n
%
 In
hi
bi
tio
n 
of
 in
fe
ct
io
n
[F63] (nmol/l)
IC
50
 (n
mo
l/l)101 102 103 104
Fig. 4. Antiviral activity of VLs against HIV primary isolates. Antiviral activity of F63 and Food and Drug Administration-
approved T-20 against HIV-1 (a and c) and HIV-2 (b and d) primary isolates. HIV infectivity was evaluated by luciferase activity
measurement. Data are displayed as percentage of infectivity inhibition (virus/no inhibitors¼0%; no virus/no inhibitors¼
background) according to the formula: [1 (light units (LU)virus/inhibitors LUbackground)/(LUvirus/noinhibitors LUbackground)]100.
Error bars correspond to SD (n¼4). (e) IC50 values of F63 and T-20 for all tested HIV primary isolates (P<0.05; P< 0.01; P<0.001; NS; t-‘test’). Bars represent mean values.F63 interact with lipid membranes, independently of
the cholesterol content. Spectral properties of lipophilic
probes such as 4-(2-[6-(dioctylamino)-2-naphthaleny-
l]ethenyl)-1-(3-sulfopropyl)pyridinium inner salt (di-
8-ANEPPS), which are responsive to variations in
membrane dipole potential, can also be exploited to
study protein–membrane interactions [43]. Excitation
spectra of di-8-ANEPPS inserted in both membrane
models underwent a redshift to higher wavelengths –
indication of a membrane dipole potential perturbation –
only in the F63 presence (Fig. 5c and d). These
observations complement the previous partition results
and support the hypothesis that F63 has unique
membrane-interacting properties, unlike VLparental. F63
also presented a binding affinity (KD) of 8 nmol/l to
N36 as determined by surface plasmon resonance
(Table S5, http://links.lww.com/QAD/A912), establish-
ing this VL as a high-affinity binder in the low nanomolar
range.Discussion
HIVentry inhibition is a key component of any antiviral
therapeutic scheme leading to impairment of de novo
infection. In this report, we selected a broad and potent
HIV fusion inhibitor from a synthetic repertoire of VLdomains. Several studies have shown that VLs tend to
aggregate less [12–14] and present higher antigen-
binding properties [44,45] than VH domains. In this
study, we went further relative to others [46,47] and
successfully selected a high-affinity VL with elongated
CDRs. Our data suggest that the screening of libraries
containing CDRs-elongated antibody formats result in
the selection of cryptic epitope binders, mimicking the
longer and more flexible CDRs found in camelids [48].
Here, we took advantage of VLs reduced size to target a
sterically restricted region on HR1 of gp41 (N36).
Together with the corresponding HR2 region, N36 is
sufficient to form the 6HB structure responsible for the
HIV fusion [19]. Accordingly, a VL–N36 interaction
would prevent the 6HB assembly, leading to HIV entry
impairment. Epitope mapping of the most potent HIV
inhibitors revealed two similar sequences within the N36
central region, previously described as part of a highly
conserved cavity (hydrophobic pocket) essential for HR2
binding [19,49]. Despite the location of D104 target
region within the F63 target sequence, antiviral activity
against HIV primary isolates was only observed with F63.
Thus, our data seem to indicate that targeting of D104
epitope is insufficient for broad neutralization of HIV.
Nevertheless, as D104 affinity was not determined,
we cannot exclude that it may influence viral inhibition.
CE: Tripti; AIDS-D-15-01276; Total nos of Pages: 11;
AIDS-D-15-01276
8 AIDS 2016, Vol 00 No 00
1.05
(a) (b)
(c) (d)
1.00
0.95
0.90
I/I
w
I/I
w
0.85 F63
VL
0.80
0.4 F63
VL
F63
VL
0.2
In
te
ns
ity
 d
iff
e
re
n
ce
 (x
10
−
3  
co
u
n
ts
)
In
te
ns
ity
 d
iff
e
re
n
ce
 (x
10
−
3  
co
u
n
ts
)
0.0
−0.2
−0.4
0.4
0.2
0.0
−0.2
−0.4
380 420 460 500
λ (nm) λ (nm)
540 580 380 420 460 500 540 580
[Lipid] (mmol/l)
0 1 2 3 4 5
1.05
1.00
0.95
0.90
0.85 F63
VL
0.80
[Lipid] (mmol/l)
0 1 2 3 4 5
Fig. 5. F63 membrane interactions. Partition profiles of F63 and control VLparental (VL) toward POPC (cellular membrane model)
(a) and POPC : cholesterol (2 : 1; virus envelopemodel) (b). F63 and VLparental were titrated with small volumes of large unilamellar
vesicles (LUV) up to final lipid concentrations, [L]. sdAb intrinsic fluorescence emission, I, was collected for each [L], and
normalized to the respective emission in the aqueous media, IW. The line represents the best fit of Eq. (1) (in supplementary
material) to one of three independent replicates. Differential excitation spectra of di-8-ANEPPS-labelled POPC (c) and
POPC : cholesterol (2 : 1) (d) liposomal membrane models in the presence of F63 or control VLparental (VL). Graphs were obtained
by subtraction of the normalized di-8-ANEPPS excitation spectra controls from the spectra in the presence of each VL
(normalization to the respective spectrum integral). The presented spectra constitute one of three independent replicates. POPC,
1-palmitoyl-2-oleyl-sn-glycero-3-phosphocholine.On the other hand, F63 epitope represents a promising
target with 60% conservation amongst HIV-1 subtypes
and even HIV types (Fig. S2, http://links.lww.com/
QAD/A912). This predicted epitope is also distinct from
the T-20 binding region that has a low genetic barrier to
drug resistance, mainly the Gly–Ile–Val sequence
(HR136–38(HXB2)) [38,50], as reinforced by the observed
F63 inhibition of T-20 resistant HIV-1 strains. Moreover,
a substitution of a single residue on 70% of the F63
predicted epitope would lead to impaired or nonfunc-
tional HIV-1 entry mutants as reported by Sen et al. [51]
(Fig. S2, http://links.lww.com/QAD/A912). F63
epitope conservation and importance for HIV fusion
together with the fact that this VL domain inhibited HIV-
1 primary isolates from distinct subtypes similarly to T-20
and HIV-2 primary isolates highlight F63 potency and
predict a high breadth for this inhibitor. Moreover, as
T-20 has a limited activity on HIV-2 [6,52], F63 could
constitute an alternative to the treatment of this HIV type.
The close proximity of gp41 to viral envelope and cellular
membrane during HIV entry questions the role ofmembranes in gp41-targeting inhibitors mechanism. For
example, T-20 shows considerable interaction with lipid
membranes [20]. Also, broadly neutralizing antibodies
2F5 and 4E10 are capable of stable epitope binding through
cross-reactive lipid interaction [53]. We have assessed F63
membrane interactions through fluorescence spectroscopy
methodologies and identified its partition toward lipid
membrane models. Interestingly, the VLparental was unable
to interact with these models, suggesting that this property
was acquired during CDRs randomization and is
associated to CDR1 and/or CDR3. From a pharmaco-
logical standpoint, membranes interaction is a desirable
property of an inhibitor mechanism [54], enabling the
establishment of local and transient reservoirs both in
the viral envelope and cellular membrane. Furthermore,
the F63 lack of a Fc immune-triggering domain avoids
cross-reactivity with lipids, a significant drawback in 2F5
and 4E10 application [55].
To our knowledge, this is the first report presenting a
synthetic VL sdAb designed as a potent inhibitor of HIV
infection. Other fusion inhibitors with an antiviral
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However, F63 combine the reduced molecular weight of
small nonantibody inhibitors with the specificity and
high-affinity of antibody paratopes and the excellent
biophysical properties and versatility of antibody formats.
Despite VHH antibody fragments were also identified as
anti-HIV inhibitors [57–61], these variable domains
target gp120 and were not synthetically randomized,
being derived from llama immunization. Owing to
protease resistance and simplicity of sdAbs, F63 may also
overcome major T-20 weaknesses, such as oral admin-
istration preclusion, high production cost, and short
half-life [62,63]. Additionally, F63 potency and biodis-
tribution may be further improved by several strategies
such as coupling of effector molecules (enzymes and
cytotoxic drugs) and inhibitor targeting to the choles-
terol-rich areas where HIV preferentially enters [64], for
example, through attachment of cholesterol-binding
peptides.
To address the expected immunogenicity of a rabbit VL,
we successfully humanized F63 by removing residues
potentially recognized as T-cell epitopes (deimmuniza-
tion) as described in Jones et al. [65]. Humanized F63
neutralized HIV-1NL4–3 laboratory-adapted strain sim-
ilarly to rabbit F63 and proved to be more stable than its
rabbit homolog because of alanine substitution of
unpaired cysteines performed along with F63 humaniza-
tion (data not shown). It is conceivable that the rabbit-
conserved cysteine at position 91 – that forms an unusual
disulfide bridge between variable and constant domains
[66] – together with the cysteine selected in CDR1
sequence were major contributors to the insolubility of
F63 during the purification process. Therefore, our
library design strategy could benefit from the replacement
of DVN by the NDT degenerate codon, which encodes
fewer cysteine residues and does not yield stop codons.
In conclusion, we successfully developed a potent and
broad fusion inhibitor of HIV-1 and HIV-2 infection
using a VL sdAb as scaffold. We validated the selection of
potent inhibitors based on a rational engineering strategy
for synthetic library design. Our findings also encourage
exploration of CDRs elongation for the design or
improvement of next generation HIV inhibitors.Acknowledgements
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